Codiak BioSciences, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
35 Cambridgepark Drive, Suite 500, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 3, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 426 % -27.3%
Debt-to-equity 218 % -27.4%
Return On Equity -37.6 % +77.8%
Return On Assets -11.8 % +72.1%
Operating Margin -156 % +62.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.8M shares +64.7%
Common Stock, Shares, Outstanding 36.8M shares +64.7%
Common Stock, Value, Issued 4K USD +100%
Weighted Average Number of Shares Outstanding, Basic 25.2M shares +12.7%
Weighted Average Number of Shares Outstanding, Diluted 25.2M shares +12.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 34.1M USD +102%
Revenue from Contract with Customer, Excluding Assessed Tax 34.7M USD +108%
Research and Development Expense 55.3M USD -8.97%
General and Administrative Expense 27.6M USD +3.46%
Operating Income (Loss) -53.3M USD +24.4%
Nonoperating Income (Expense) 35.9M USD
Net Income (Loss) Attributable to Parent -17.4M USD +75.7%
Earnings Per Share, Basic -0.77 USD/shares +20.6%
Earnings Per Share, Diluted -0.77 USD/shares +20.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 51.8M USD -47.5%
Cash, Cash Equivalents, and Short-term Investments 51.8M USD -47.5%
Assets, Current 61.2M USD -41.1%
Property, Plant and Equipment, Net 20.5M USD -30.1%
Operating Lease, Right-of-Use Asset 21M USD -1.43%
Assets 134M USD -15.3%
Accounts Payable, Current 1.96M USD -2.1%
Employee-related Liabilities, Current 4.27M USD -27.1%
Accrued Liabilities, Current 8.13M USD -12.8%
Liabilities, Current 14.5M USD -37.4%
Operating Lease, Liability, Noncurrent 32.6M USD -6.03%
Liabilities 95.5M USD -23.5%
Retained Earnings (Accumulated Deficit) -359M USD -5.1%
Stockholders' Equity Attributable to Parent 38.9M USD +14.5%
Liabilities and Equity 134M USD -15.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD -6.18%
Net Cash Provided by (Used in) Financing Activities 589K USD -99.1%
Net Cash Provided by (Used in) Investing Activities -182K USD +88.1%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 36.8M shares +64.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.4M USD -149%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 55.9M USD -45.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 516K USD -8.35%
Operating Lease, Liability 35.6M USD -4.09%
Payments to Acquire Property, Plant, and Equipment 182K USD -88.1%
Lessee, Operating Lease, Liability, to be Paid 50.3M USD -9.29%
Operating Lease, Liability, Current 3.01M USD +23.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.63M USD +5.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.44M USD +5.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14.7M USD -19.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.82M USD +4.99%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.02M USD +4.92%
Operating Lease, Payments 1.56M USD +5.06%
Additional Paid in Capital 398M USD +5.94%
Depreciation, Depletion and Amortization 5.03M USD +6.61%
Share-based Payment Arrangement, Expense 9.93M USD -2.44%
Interest Expense 2.61M USD -6.75%